Clinical trial - taking part

TauRx’s tau aggregation inhibitors are the product of nearly 30 years of research, preclinical and clinical investigations.

Our second-generation tau aggregation inhibitor, has already completed three separate Phase 3 trials: two in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

We are undertaking our latest phase 3 clinical trial, named LUCIDITY. The design of this trial accounts for participants with mild cognitive impairment, mild Alzheimer’s, and mild-moderate Alzheimer’s.

Over 500 patients have been recruited to the trial and it is now closed to screening. The trial uses well-accepted cognitive and functional assessment scales to assess the effectiveness of the drug in delaying the progression of Alzheimer’s disease. It includes an open-label phase during which all participants will receive the drug at the predicted optimal dose of 16mg per day.

Additional information on the study is also available here.